"Drug Discovery Chemistry" is a conference organized by the Cambridge Healthtech Institute that brings together representatives from the pharmaceutical, biotechnology, and academic sectors for interactions focused on the discovery and optimization of small molecule drug candidates. This year's Drug Discovery Chemistry 2024 (DDC 2024) will take place from April 1-4, 2024 in San Diego, USA, and will feature keynotes from Dr. Barry Sharpless of Scripps Research Institute and Professor Daniel Nomura of UC Berkeley.
As of today, 52 poster presentations have been accepted for DDC 2024, and in this post, I'll try to categorize and analyze the topics of these presentations.
As DDC 2024 is an international conference, organizations from various countries participated.
Of these, North America had the highest percentage of presentations at 40.38%.
This was followed by Europe at 36.54% and Asia at 17.31%.
In Europe, the United Kingdom has the largest share at 57.89%, followed by Hungary, Switzerland, Austria, Ukraine, and Denmark.
In Asia, South Korea had the highest percentage at 33.33%, followed by Japan, China, Taiwan, and Hong Kong.
If we break down the 52 submissions by affiliation, we see that a total of 40 companies/institutions contributed posters.
Of these, about 60% are for-profit, about 27% are universities, and 13% are non-profit research organizations.
In the case of for-profit organizations, we can see that famous companies in the pharmaceutical industry such as Hoffmann-La Roche in Switzerland, Cresset in the UK, Simulation Plus in the US, and CIMPLRX in Korea along with our company Hits participated.
In the case of universities, the list includes renowned universities such as Yale University, the University of Michigan, the University of Hong Kong, and Kyungpook National University in Korea.
Non-profit research organizations include the National Institute of Health in the US, the Cambridge Crystallographic Data Center in the UK, and the National Health Research Institute in Taiwan.
The poster presentations at this meeting are categorized into eight topics below. The current list of poster presentations on the webpage does not categorize the topics, so I have tried to infer and categorize them based on the titles.
From left to right.
FBDD was the most popular topic, accounting for 26.92% of all presentations.
This was followed by AI/ML for Early Drug Discovery
Molecular disruptors/adhesives for early drug discovery accounted for 17.31%. 15.38%.
Small molecule immunomodulators and coding libraries both accounted for 9.62%.
Protein-protein interactions and RNA-formulated small molecule drugs accounted for 5.77%,
Oral peptides and macrocyclics at 3.85%.
Oral peptides and macrocycles accounted for the smallest percentage.
We are also scheduled to present our Hyper Lab in the poster session at DDC 2024. We look forward to seeing you at DDC 2024 this year, and we'll be posting more DDC-related posts in the future.
Thank you.
